Orion Oyj (OTCMKTS:ORINY) Hits New 52-Week High - What's Next?

Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $35.12 and last traded at $35.12, with a volume of 146 shares. The stock had previously closed at $33.52.

Orion Oyj Stock Performance

The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The stock has a market cap of $10.08 billion, a P/E ratio of 28.35 and a beta of 0.17. The company's 50-day simple moving average is $30.67 and its 200 day simple moving average is $27.45.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $373.03 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, sell-side analysts expect that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The firm also recently declared a dividend, which was paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th were given a dividend of $0.4478 per share. This is a positive change from Orion Oyj's previous dividend of $0.24. The ex-dividend date of this dividend was Monday, April 7th. Orion Oyj's dividend payout ratio is presently 24.43%.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.